NASDAQ:SAVA Archives - BioPharmaJournal

Cassava Sciences Inc. (NASDAQ: SAVA) Launches New Clinical Website Offering Information...

Gavins Felicity - January 3, 2022 0

Journal of Neuroscience Didn’t Find Data Manipulation Evidence in Research Article...

Matt Wade - November 17, 2021 0

Annovis Bio Inc (NYSEAMERICAN: ANVS), Cassava Sciences Inc (NASDAQ: SAVA), Honest...

Kate Hudson - October 11, 2021 0

Cassava Sciences Inc. (NASDAQ: SAVA) Releases Clinical Data On Simufilam In...

Matt Wade - September 28, 2021 0

Cassava Sciences Inc. (NASDAQ:SAVA) Released Addition Phase 2b Clinical Study Results...

Ward Sport - November 10, 2020 0

CTAD 2020 Picks Cassava Sciences Inc.’s (NASDAQ:SAVA) Phase 2b Sumifilam Study...

Matt Wade - October 14, 2020 0

Cassava Sciences Inc. (NASDAQ:SAVA) Demonstrates Directional Improvement In Alzheimer’s Patients Treated...

Matt Wade - September 17, 2020 0

The USAN Announces a Commercial Brand Name for PTI-125; Lead Drug...

Kate Hudson - September 1, 2020 0

Cassava Sciences Inc (NASDAQ:SAVA) Expects To Release Clinical Results Of Phase...

Kate Hudson - August 26, 2020 0

Chimerix Inc (NASDAQ: CMRX) Receives $25.3 Million Procurement Contract For TEMBEXA

Kate Hudson - July 4, 2022 0

Chimerix Inc (NASDAQ: CMRX) has received a $25.3 million contract agreement from the Public Health Agency of Canada for the procurement of TEMBEX (brincidofovir)....

Regulus Therapeutics Inc (NASDAQ: RGLS) Pleased after FDA Approved its Orphan...

July 1, 2022

Cannabis Stocks Deeply Oversold with Big Growth Ahead (TLRY, SGMD, OGI,...

June 30, 2022

Ocugen Inc (NASDAQ: OCGN) Announces the Successful Publication of Positive Outcomes...

June 30, 2022

Why Your Body Needs Nitric Oxide Boost Beets For More Energy...

June 28, 2022

Tag: NASDAQ:SAVA

Recent Post